News On TCR2 Therapeutics Inc. (TCRR) Now Under ADAP
News On TCR2 Therapeutics Inc. (TCRR) Now Under ADAP
Dow JonesJun 1, 2023 17:08 ET
Adaptimmune Completes Merger With Fellow Immunology Company TCR2
Seeking AlphaJun 1, 2023 17:02 ET
Adaptimmune Announces Completion of Strategic Combination With TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 1, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced completion of an all-stock transaction in which Adaptimmune has combined with TCR2 Therapeutics Inc. (NASDAQ: TCRR) to create a preeminent T-cell therapy company to treat solid tumors.
newsfileJun 1, 2023 15:29 ET
TCR2 Therapeutics Target Price Raised to $2.11 From $1.72 at Mizuho Securities
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Dow JonesMay 12, 2023 06:56 ET
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones closed slightly lower on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in pe
BenzingaMay 11, 2023 09:25 ET
TCR2 Therapeutics (TCRR) Receives a Hold From Mizuho Securities
TipRanksMay 11, 2023 08:45 ET
Recap: TCR2 Therapeutics Q1 Earnings
TCR2 Therapeutics (NASDAQ:TCRR) reported its Q1 earnings results on Thursday, May 11, 2023 at 06:30 AM.Here's what investors need to know about the announcement.EarningsTCR2 Therapeutics missed estima
BenzingaMay 11, 2023 08:11 ET
TCR2 Therapeutics Q1 EPS $(1.03) Down From $(0.76) YoY
TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(1.03) per share. This is a 35.53 percent decrease over losses of $(0.76) per share from the same period last year.
BenzingaMay 11, 2023 06:46 ET
Express News | TCR2 Therapeutics 1Q Loss/Shr $1.03 >TCRR
Moomoo 24/7May 11, 2023 06:30 ET
Press Release: TCR(2) Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
TCR(2) Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
Dow JonesMay 11, 2023 06:30 ET
Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights About 250+ Companies and 300+ Drugs
PRNewswireMay 8, 2023 11:02 ET
FUBO, MULN and BAK Are Among Pre-market Gainers
Seeking AlphaMay 8, 2023 08:24 ET
Ribbon Communications And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones jumped more than 500 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in
BenzingaMay 8, 2023 07:43 ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, ROCC, TCRR
PRNewswireApr 27, 2023 11:08 ET
Fate Therapeutics (NASDAQ:FATE) and TCR2 Therapeutics (NASDAQ:TCRR) Head to Head Comparison
Fate Therapeutics (NASDAQ:FATE – Get Rating) and TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two busine
Financial News LiveApr 27, 2023 05:49 ET
TCR2 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR2 Therapeutics Inc. - TCRR
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of TCR2 Therapeutic
BusinesswireApr 26, 2023 14:07 ET
Head to Head Analysis: Fate Therapeutics (NASDAQ:FATE) & TCR2 Therapeutics (NASDAQ:TCRR)
TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) and Fate Therapeutics (NASDAQ:FATE – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two compan
Defense WorldApr 20, 2023 04:58 ET
Adaptimmune, TCR Therapeutics Set May 30 for Shareholder Votes on Deal
Seeking AlphaApr 18, 2023 16:40 ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ROCC, KBAL, ADAP, TCRR
NEW YORK, April 11, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breache
PR NewswireApr 11, 2023 13:40 ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, ADAP, TCRR
NEW YORK, April 6, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
PR NewswireApr 6, 2023 11:25 ET
No Data
No Data